By admin 
CureSearch for Children’s Cancer, a leading national non-profit foundation dedicated to accelerating the development of new and better treatments for pediatric cancer, has officially announced the appointment of Osama Alsaleh to its Board of Directors. This strategic addition comes at a pivotal moment for the organization as it seeks to bridge the gap between traditional medical research and the fast-paced world of venture capital, technology, and global innovation. Alsaleh, a distinguished leader in healthcare technology and investment, brings a multifaceted background that spans strategic partnerships, health equity, and regulatory compliance. His appointment is expected to catalyze CureSearch’s mission by leveraging his extensive network in the venture capital and startup ecosystems to address the persistent funding and representation gaps in pediatric oncology.
As the current Head of Partnerships at Plug and Play Health—the healthcare arm of the world’s most active venture capital firm and global innovation platform—Alsaleh is uniquely positioned to help CureSearch navigate the complexities of the modern healthcare landscape. His career has been defined by a commitment to advancing global health solutions through cross-industry collaboration, a skill set that CureSearch identifies as essential for overcoming the unique hurdles of pediatric drug development. By integrating Alsaleh’s expertise into its leadership, CureSearch aims to foster a more robust pipeline of innovative therapies for children who currently have limited treatment options.
A Career Defined by Innovation and Health Equity
The professional trajectory of Osama Alsaleh reflects a deep-seated commitment to transforming healthcare through technology and strategic philanthropy. Before his leadership role at Plug and Play Health, Alsaleh held several high-impact positions at Oracle Health (formerly Cerner), where he was instrumental in shaping the company’s approach to social determinants of health and global health initiatives. One of his most notable achievements was the spearheading of Oracle’s health equity team. In this capacity, he developed transformative strategies focused on accessibility and the systemic factors that influence patient outcomes, ensuring that technological advancements in healthcare reached underserved populations.
Beyond strategy, Alsaleh’s experience includes direct involvement in large-scale philanthropic resource allocation. During his tenure at Oracle, he served on the Oracle Charitable Foundation Clinical Decision Committee, where he contributed to the evaluation and distribution of more than $42 million in healthcare grants. This experience provided him with a rigorous understanding of how to assess medical projects for both scientific merit and community impact—a perspective that aligns closely with CureSearch’s model of funding high-potential clinical trials and research.
Alsaleh’s expertise also extends into the regulatory and governmental spheres. He has served as an advisor on quality reporting measures and has collaborated with various high-level entities, including the Centers for Medicare & Medicaid Services (CMS). His involvement with the White House COVID-19 Taskforce and the U.S. State Department highlights his ability to operate at the intersection of public policy and private innovation. Furthermore, his work with international organizations such as the World Bank Group and the World Health Organization (WHO) has provided him with a global perspective on healthcare infrastructure and the necessity of sustainable, scalable solutions.
Addressing the Pediatric Cancer Funding Gap
The appointment of Alsaleh is a direct response to the systemic challenges inherent in pediatric oncology. While cancer remains the leading cause of death by disease for children in the United States, the field of pediatric drug development often struggles to attract the same level of investment as adult oncology. According to data from the National Cancer Institute (NCI), pediatric cancer research historically receives only about 4% of the total federal funding allocated for cancer research. This disparity is further exacerbated in the private sector, where the relatively small market size of pediatric patients can deter traditional venture capital and pharmaceutical investment.
CureSearch has long advocated for a shift in this paradigm, focusing on a "venture philanthropy" model that de-risks early-stage research to make it more attractive for commercial development. Alsaleh’s background at Plug and Play Health—a firm that has accelerated thousands of startups and maintains partnerships with hundreds of corporations—is expected to be a game-changer in this regard. By connecting pediatric researchers with tech-driven startups and private investors, CureSearch hopes to bypass traditional bottlenecks in the drug development pipeline.
The statistics surrounding pediatric cancer underscore the urgency of this mission. Every year, more than 15,000 children and adolescents in the U.S. are diagnosed with cancer. While survival rates for some forms of the disease have improved significantly over the last few decades, others remain stubbornly low. Furthermore, many survivors face long-term health complications due to the toxicity of current treatments, which are often adapted from adult protocols rather than being designed specifically for developing bodies. Alsaleh’s focus on innovation is intended to drive the development of "smarter" therapies that are both more effective and less harmful.
Strategic Perspectives from Board Leadership
The leadership at CureSearch has expressed high confidence in the unique perspective Alsaleh brings to the organization. Jared Brancazio, Chair of the CureSearch Board of Directors, emphasized the importance of bridging the gap between scientific discovery and financial investment. "Osama brings a unique and highly valuable perspective to CureSearch," Brancazio stated. "His ability to connect innovation, investment, and healthcare will help expand our reach and unlock new opportunities to advance critical research for children with cancer. We are excited to have him join the board at this important time for our organization."
For his part, Alsaleh has identified the underrepresentation of pediatrics in the innovation ecosystem as a primary motivation for joining the board. He noted that while the broader healthcare technology sector is booming, children often remain an afterthought in the development of new tools and therapies. "Throughout my work, I have consistently observed that innovations focused on pediatrics, particularly pediatric oncology, remain significantly underfunded and underrepresented within mainstream venture capital and innovation ecosystems," Alsaleh said.
His strategy for CureSearch involves utilizing his professional network to create a more inclusive environment for pediatric health. "By leveraging my network across venture capital, startups, healthcare institutions, and technology companies, I aim to help attract new technologies, strategic partners, and resources that can accelerate progress toward cures for children with cancer," he added. This approach aligns with a growing trend in the non-profit sector to utilize private-sector methodologies to achieve social and medical breakthroughs.
Broader Implications for the Future of Pediatric Oncology
The inclusion of a venture capital and technology expert on a prominent medical non-profit board reflects a broader evolution in how medical research is funded and executed. In an era where artificial intelligence, genomic sequencing, and precision medicine are redefining the limits of what is possible, the role of a "convenor"—someone who can bring together disparate sectors—is increasingly vital.
Alsaleh’s appointment may signal a new phase for CureSearch, characterized by:
- Accelerated Tech Integration: Utilizing AI and big data to identify potential drug candidates and optimize clinical trial designs, potentially reducing the time it takes to move from the lab to the bedside.
- Expanded Corporate Partnerships: Tapping into the CSR (Corporate Social Responsibility) and ESG (Environmental, Social, and Governance) mandates of major technology and healthcare firms to secure non-traditional funding sources.
- Global Scalability: Applying lessons learned from the WHO and World Bank to ensure that advancements in pediatric oncology are accessible not just in the U.S., but on a global scale, particularly in low- and middle-income countries where survival rates are significantly lower.
The regulatory environment also stands to benefit from this synergy. With the passage of the RACE for Children Act (Research to Accelerate Cures and Equity), which requires companies developing adult cancer drugs to also investigate their potential in pediatric populations, there is a greater need for intermediaries who understand both the regulatory requirements and the commercial incentives. Alsaleh’s history of advising on CMS initiatives and working with the U.S. State Department provides him with the necessary background to navigate these evolving legal landscapes.
Conclusion and Organizational Outlook
CureSearch for Children’s Cancer remains committed to its goal of ending pediatric cancer by funding the most promising research wherever it may be found. The addition of Osama Alsaleh to the Board of Directors is a testament to the organization’s forward-thinking approach. By blending clinical expertise with the agility of the venture capital world, CureSearch is positioning itself to overcome the economic and systemic barriers that have historically slowed progress in pediatric medicine.
As Alsaleh begins his tenure, the organization and its stakeholders look forward to a period of increased collaboration and innovative breakthroughs. The integration of his experience in health equity ensures that as new treatments are developed, they will be pursued with an eye toward accessibility and fairness, ensuring that every child, regardless of their background, has a fighting chance against cancer. The medical and investment communities alike will be watching closely as this partnership seeks to redefine the standards of care and funding in the fight against childhood cancer.
